NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference.
Details of the company’s presentation is as follows:
Aegis Virtual Conference
Format: Corporate Presentation
Date and Time: Wednesday, May 3rd, 11:30 a.m. ET
Location: Virtual
A live webcast of the presentation will be available on atai’s website under Events on the Investors section of the atai website: https://ir.atai.life/news-events/events/. An archived replay of the webcast will be available for up to 30 days following the presentation.
About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.
atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.
Contact Information
Investor Contact:
Stephen Bardin
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Allan Malievsky
Senior Director, External Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.06 |
| Daily Change: | 0.04 1.98 |
| Daily Volume: | 1,711,477 |
| Market Cap: | US$345.670M |
May 14, 2025 March 17, 2025 March 11, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
